Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Gain a basic understanding of the legislative process and health policy advocacy so that you can make sure the voice of oncology nurses is heard loud and clear. This free self-directed, self-paced course demonstrates how, in a short period of time, you can influence critical policy-making decisions.
More than 40% of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer had an overall response receiving dostarlimab-gxly (Jemperli), and more than 90% of those lasted six months or longer during the drug’s clinical trials. Those results led the U.S. Food and Drug Administration (FDA) to grant the agent its original accelerated approval in 2021 for the indication. FDA expanded the accelerated approval later that year to include all recurrent or advanced solid tumors with dMMR demonstrated through an FDA-approved diagnostic test.
The Fundamentals of Chemotherapy Immunotherapy Administration Renewal Course builds on the lessons you received in the Fundamentals of Chemotherapy Immunotherapy Administration Course to ensure that your chemotherapy and immunotherapy knowledge remains current and you’re continuing to progress as an experienced oncology RN.
The ONS/ONCC Chemotherapy Immunotherapy Certificate Renewal Course will guide you through four strategically planned case studies to ensure that your chemotherapy and immunotherapy knowledge stays current and you’re continuing to progress as an experienced oncology RN.
Prepare for your AOCNP® certification exam with the AOCNP® Certification Review Bundle. This bundle offers access to seven online courses and the latest edition of the Advanced Oncology Nursing Certification Review and Resource Manual.
In July 2020, the U.S. Food and Drug Administration approved decitabine and cedazuridine (Inqovi®) tablets for the treatment of adults with myelodysplastic syndromes (MDS).
After more than 93% of patients maintained nadir serum asparaginase activity in the therapy’s clinical trials, on June 30, 2021, the U.S. Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)–rywn (RylazeTM) for use as a component of a multiagent chemotherapeutic regimen for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who have developed hypersensitivity to E. coli-derived asparaginase.
These free intravenous cancer therapy education sheets provide oncology nurses a trusted and reliable resource to use as part of a comprehensive treatment education discussion with patients and caregivers.
This course will provide you with a foundational level of knowledge about antineoplastic therapy, how they are used in cancer and noncancer treatment, and the effects on the patients who receive them.